USA: Cell and Gene Therapy Solutions JH University Selects Orgenesis’ Pocare Platform To Develop Gene Technologies
Orgenesis has entered into an agreement with the John Hopkins University under which the institue will make use of Orgenesis’ point-of-care (Pocare) platform to devlop and supply a wide range of cell and gene therapies and technologies.
Maryland/USA – Orgenesis, a provider of point-of-care cell and gene therapy development, processing and treatment solutions (Pocare), has recently announced that it has entered into a collaboration agreement with the John Hopkins University (JHU). Under the terms of the agreement, JHU will utilise Orgenesis’ Point-of-Care (Pocare) platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies.
Vered Caplan, CEO of Orgenesis, stated, “JHU has unparalleled capabilities in the cell and gene therapy sector. Our Pocare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems and other advanced cell processing technologies at the point of care. We look forward to utilising our Pocare platform to support JHU’s growing development and processing needs in order to advance and accelerate cell and gene based clinical therapeutic research. We believe this collaboration with JHU, a clear leader in the field of cell and gene therapy, further validates the significant value proposition of our Pocare platform. Moreover, this is the third major agreement signed by an international institution in recent months to utilise Orgenesis’ Pocare solutions.”